Syros to Participate in Upcoming Virtual Investor Conferences in March

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming virtual investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Cowen 42nd Annual Healthcare Conference Date: Monday, March 7 Panel Title: Novel Oncology Targets Panel Time: 12:50 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference Date: Wednesday, March 16 Presentation Time: 3:20 p.m. ET

To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005020/en/

Media Contact: Courtney Solberg Syros Pharmaceuticals 917-698-9253 [e-mail]

Investor Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 [e-mail]